NRx Pharmaceuticals announced that FDA has given the company clearance to proceed with human trials to treat Chronic Pain under the Investigational New Drug, or IND, application filed with the FDA for the use of NRX-101. The IND application leverages pioneering research on the use of D-cycloserine in the treatment of chronic pain and the recent licensure by NRx of a US Patent for the use of D-cycloserine in the treatment of pain.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NRXP:
- NRx Pharmaceuticals sees potential NDA filing for NRX-100 in 2024
- NRx Pharmaceuticals signs data sharing agreement for ketamine treatment
- NRx Pharmaceuticals announces agreement with LifeSci Associates
- NRx Pharmaceuticals announces data on in vitro activity of NRX-101
- NRx Pharmaceuticals announces submission of IND application for NRX-101